Literature DB >> 6201562

Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma.

S K Foung, S Perkins, A Raubitschek, J Larrick, G Lizak, D Fishwild, E G Engleman, F C Grumet.   

Abstract

A human-mouse cell line that is hypoxanthine-aminopterin-thymidine sensitive and ouabain resistant was derived from a fusion between human B lymphocytes and a mouse myeloma line. This new mutant, when fused to a relatively unstable EBV-transformed B cell secreting a human monoclonal anti-A (red blood cell antigen) antibody, resulted in stable hybridomas capable of long term production of the specific human monoclonal antibody. Furthermore, some of the hybrid clones secreted antibody in far greater titer than the original EBV cell line. We conclude that fusion to this human-mouse line is an efficient approach to the production of human monoclonal alloantibodies and an effective method of 'rescuing' secretion of desired antibody from EBV cell lines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201562     DOI: 10.1016/0022-1759(84)90392-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  15 in total

1.  Development of human monoclonal antibodies: A review.

Authors:  T Lindl
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Production of human monoclonal IgG and IgM antibodies with anti-D (rhesus) specificity using heterohybridomas.

Authors:  K M Thompson; M D Melamed; K Eagle; B D Gorick; T Gibson; A M Holburn; N C Hughes-Jones
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

Review 3.  Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies.

Authors:  Scott A Smith; James E Crowe
Journal:  Microbiol Spectr       Date:  2015-02

Review 4.  Antibody engineering, a strategy for the development of monoclonal antibodies.

Authors:  O T Schönherr; E H Houwink
Journal:  Antonie Van Leeuwenhoek       Date:  1984       Impact factor: 2.271

5.  Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides.

Authors:  A B Lang; E Fürer; J W Larrick; S J Cryz
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

6.  Human IgG and IgM monoclonal antibodies against autologous melanoma produced by Epstein-Barr-virus-transformed B lymphocytes.

Authors:  J M Kirkwood; J E Robinson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels.

Authors:  I F Charo; S Shak; M A Karasek; P M Davison; I M Goldstein
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

8.  An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies.

Authors:  Xiaocong Yu; Patricia A McGraw; Frances S House; James E Crowe
Journal:  J Immunol Methods       Date:  2008-05-05       Impact factor: 2.303

9.  Heterohybridomas that secrete high levels of pseudomonas-specific therapeutic human monoclonal antibodies: their generation and large scale growth in an automated hollow fiber cell culture system.

Authors:  M C Gammon; M H Banas; L E Boccumini; N H Sigal; H J Zweerink
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

10.  Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides.

Authors:  M Pollack; A A Raubitschek; J W Larrick
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.